William E. Wade, Pharm.D., FASHP, FCCP

Professor

Department of Clinical and Administrative Pharmacy
University of Georgia College of Pharmacy
Athens, Georgia 30602
Phone 706-542-5316
Fax 706-542-5228
E-mail: bwade@rx.uga.edu

Education:

1975   B.S., Pharmacy
University of Georgia College of Pharmacy, Athens, Georgia
1985   Pharm.D.
University of Georgia College of Pharmacy, Athens, Georgia

Research Interests:

My primary interests have focused on pharmacoeconomic and clinical outcomes research. Cost studies conducted have focused on deep venous thrombosis prophylaxis in various high risk indications. Clinical outcomes research projects have focused on both the acute care medical and outpatient ambulatory environment. I plan to play a major role in the performance of translational studies in the acute care hospital setting.

Selected Publications

Wade, W.E., McCall, C.Y. Pharmacist-managed aminoglycoside therapy in combination with a beta-lactam agent in the treatment of nosocomial pneumonia in critically ill patients. Pharmacotherapy 1995; 15(2):216-9.

Wade, W.E., Spruill, W.J.. Cost analysis of the American College of Chest Physicians guidelines for deep vein thrombosis prophylaxis in patients undergoing orthopedic arthroplastic surgery. Pharmacotherapy 1997; 17(6):1286-91.

Wade, W.E.. Cost-effectiveness of venous thrombosis prophylaxis following ischemic stroke: As assessment of currently available literature. Thromb Res 1998;89:199-202.

Wade, W.E. Cost-effectiveness of venous thrombosis prophylaxis after ischemic stroke. Am J Phys Med Rehabil 1998;77(3):267-8. (Invited)

Wade, W.E., Chisholm, M.A. Cost-Effectiveness Analysis of Deep Vein Thrombosis Prophylaxis in Internal Medicine Patients. Thromb Res 1999;94:65-8.

Wade, W.E. Cost-effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery. Am J Orthopedics 1999;28(4):229-231.

Wade, W.E., Martin, B.C., Kotzan, J.A., Spruill, W.J., Chisholm, M.A., Perri, M. Formulary management of low molecular weight heparins. PharmacoEconomics 2000; 17(1):1-12. (Adis publication) Invited.

Wade, W.E., Chisholm, M.A.. Deep Venous Thrombosis Prophylaxis in Trauma: Cost Analysis. Blood Coag Fibrinol 2000;11(1):101-106.

Wade, W.E., Hawkins, D.W. Cost-effectiveness of outpatient anticoagulant prophylaxis after total joint arthroplasty. Orthopedics 2000;23(4):335-339.

Wade, W.E., Chisholm, M.A. Cost-effectiveness of deep venous thrombosis prophylaxis after hip fracture. Am J Orthopedics 2000;29(5):397-399.

Wade WE, Chisholm MA. Venous thrombosis after acute spinal cord injury: cost analysis of prophylaxis guidelines. Am J Phys Med Rehabil 2000; 79:504-508.

Wade WE, Spruill WJ. Cost comparison of tinzaparin versus enoxaparin as deep vein thrombosis prophylaxis in spinal cord injury: preliminary data. Blood Coagulation and Fibrinolysis 2001; 11(7): 619-625.

[ ABOUT THE COLLEGE | ADMISSIONS | ACADEMICS | ALUMNI AFFAIRS | CE | DEVELOPMENT | RESOURCES ]